Relationship Between Symptoms, Retinal Morphology, and the Nigrostriatal Dopamine System in Parkinson's Disease

Inclusion Criteria:

1. Willing and able to give informed consent.

2. Between the ages of 50-80 years old.

3. Male or female with idiopathic PD who fulfill UK PD Society brain bank criteria for
diagnosis of Parkinson's disease.

4. Early stage subjects will need to have Unified Parkinson's Disease Rating Scale
(UPDRS) motor scores of < 10, be within 3 years of diagnosis, and not requiring
dopaminergic therapy

5. Later stage subjects will need to have Unified Parkinson's Disease Rating Scale motor
scores of > 20 and be > 5 years from diagnosis

6. If female, one of the following three scenarios must apply:

- at least two years post-menopausal

- surgically sterile

- negative urine pregnancy test, and following a reliable method of birth control
(oral contraceptive, intrauterine device, contraceptive implant, barrier, or
abstinence) for at least two months prior to entry, and agreeing both to follow a
reliable method of birth control, and (if relevant) to desist from breast feeding
during, and for two weeks following tracer administration.

Exclusion Criteria:

1. Abrupt onset of Parkinsonism

2. 'Other Parkinson-like syndromes (e.g. progressive supranuclear palsy, multiple system
atrophy)

3. Any condition that would preclude successful completion of SPECT scanning

4. Use of anti-coagulant therapy

5. Any clinically significant eye disease that would complicate interpretation of OCT
data

6. Use of any drugs that would alter or interfere with tracer binding for SPECT imaging
studies (ex., cocaine, amphetamines, methylphenidate, ephedrine, phentermine,
bupropion, fentanyl, selective serotonin reuptake inhibitors).

7. Known sensitivity to the imaging agent or to Lugol's solution or to potassium
perchlorate.

8. History or presence of severe renal disease.